Clinical Trial Update: Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of iparomlimab and tuvonralimab with lenvatinib and chemotherapy for resectable esophageal squamous cell carcinoma; the study is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Changhai Hospital | Conditions: Esophageal Squamous Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING